IRIS UniCatt

Orlandi, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.299
AS - Asia 2.649
EU - Europa 2.386
SA - Sud America 779
AF - Africa 107
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.191
SG - Singapore 1.237
BR - Brasile 657
DE - Germania 608
CN - Cina 578
SE - Svezia 454
IT - Italia 343
VN - Vietnam 259
IN - India 154
FR - Francia 152
GB - Regno Unito 142
IE - Irlanda 129
PL - Polonia 129
FI - Finlandia 117
ID - Indonesia 98
RU - Federazione Russa 74
AR - Argentina 59
HK - Hong Kong 58
UA - Ucraina 55
BD - Bangladesh 53
CA - Canada 49
MX - Messico 42
JP - Giappone 41
CI - Costa d'Avorio 38
TR - Turchia 37
ES - Italia 32
AT - Austria 28
ZA - Sudafrica 28
KR - Corea 27
EC - Ecuador 22
NL - Olanda 21
BE - Belgio 18
IR - Iran 18
CO - Colombia 16
IQ - Iraq 14
LT - Lituania 14
RO - Romania 14
MA - Marocco 13
SA - Arabia Saudita 13
CZ - Repubblica Ceca 11
PK - Pakistan 11
CH - Svizzera 10
CL - Cile 8
IL - Israele 7
RS - Serbia 7
VE - Venezuela 7
AU - Australia 6
LU - Lussemburgo 6
UZ - Uzbekistan 6
EG - Egitto 5
KE - Kenya 5
KZ - Kazakistan 5
TN - Tunisia 5
BO - Bolivia 4
LB - Libano 4
MY - Malesia 4
NO - Norvegia 4
PY - Paraguay 4
BG - Bulgaria 3
GE - Georgia 3
HN - Honduras 3
HU - Ungheria 3
LV - Lettonia 3
PH - Filippine 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
CR - Costa Rica 2
DZ - Algeria 2
EU - Europa 2
GA - Gabon 2
JM - Giamaica 2
JO - Giordania 2
KW - Kuwait 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BH - Bahrain 1
CD - Congo 1
CG - Congo 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IM - Isola di Man 1
KG - Kirghizistan 1
LC - Santa Lucia 1
LK - Sri Lanka 1
MD - Moldavia 1
MU - Mauritius 1
PA - Panama 1
PE - Perù 1
Totale 9.224
Salva come PNG Salva come JPEG
Città #
Singapore 604
Chandler 487
Ashburn 375
New York 132
Beijing 130
Dublin 122
Warsaw 119
Chicago 115
Los Angeles 113
Munich 95
Rome 91
Hyderabad 88
Hefei 87
Ho Chi Minh City 85
Fairfield 78
Houston 73
Wilmington 73
Jakarta 72
The Dalles 69
São Paulo 66
Hanoi 64
San Mateo 64
Boston 54
Milan 54
Frankfurt am Main 51
Hong Kong 51
Ann Arbor 48
Princeton 47
Woodbridge 47
Turku 46
Moscow 43
Nanjing 40
Abidjan 38
Seattle 37
Helsinki 36
London 36
Cattolica 34
Jacksonville 34
Tokyo 33
Cambridge 32
Buffalo 29
Dearborn 29
Kent 28
Redwood City 28
Dallas 27
Marseille 26
Seoul 26
Nuremberg 25
Izmir 22
Lappeenranta 22
Nürnberg 21
Salt Lake City 21
Düsseldorf 18
Brooklyn 17
Phoenix 17
Bremen 16
Brussels 16
Rio de Janeiro 16
Santa Clara 16
Toronto 16
Montreal 15
Boardman 14
Nanchang 14
Porto Alegre 14
Stockholm 14
Chennai 13
Haiphong 13
Johannesburg 13
Orem 13
Poplar 13
Tampa 13
Dhaka 12
Lancaster 12
Lawrence 12
Mexico City 12
Salvador 12
San Francisco 12
Curitiba 11
Denver 11
Guangzhou 11
Hangzhou 11
Manchester 11
Querétaro 11
Vienna 11
Amsterdam 10
Lauterbourg 10
Mountain View 10
San Diego 10
Augusta 9
Brasília 9
Da Nang 9
Elk Grove Village 9
Fremont 9
Mumbai 9
North Bergen 9
Tianjin 9
Washington 9
Andover 8
Bari 8
Belo Horizonte 8
Totale 4.842
Salva come PNG Salva come JPEG
Nome #
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 292
Neoadjuvant chemotherapy in breast cancer: An advanced personalized multidisciplinary prehabilitation model (apmp-m) to optimize outcomes 280
Diagnosis and management of breast lymphoma: A single-institution retrospective analysis 240
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 216
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 204
Diagnosis and treatment of bone metastases in breast cancer: Radiotherapy, local approach and systemic therapy in a guide for clinicians 200
Mastectomy in precision oncology era: Myth or reality? 177
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 171
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 153
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report 146
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis 142
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 139
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 138
AMAROS Study: Overall Survival in Breast Cancer Subtypes 137
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 137
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 136
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 127
Immediate prosthetic breast reconstruction after nipple-sparing mastectomy: Traditional subpectoral technique versus direct-to-implant prepectoral reconstruction without acellular dermal matrix 127
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 127
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 126
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies 121
Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis 120
Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: Preliminary experience with clinically node negative patients after systemic treatment 120
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 119
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 119
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 114
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 113
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis 111
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 111
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 110
OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer 108
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 108
Menopausal hormone therapy: What should be kept in mind for a personalized choice in a shared decision-making 106
Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: A change of paradigm in a case series 103
Targeted Therapy in Advanced Gastric Carcinoma:the Future is Beginning 101
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 101
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2 98
Diffuse liver infiltration by lobular breast carcinoma: Shear wave elastography as gold standard imaging study. 98
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 98
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial 97
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 96
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analisys 93
Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis 92
LUX-Lung 7: is there enough data for a final conclusion? 91
Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: A prospective clinical trial based on cisplatin feasibility 89
Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020 88
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting 85
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 84
Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria 83
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope 83
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy 81
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 81
Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters 80
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 79
Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results 79
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors 78
Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes 78
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA 78
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 77
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials 76
Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy 76
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study 74
Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians 74
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience 71
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysis 71
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 71
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis 69
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse 69
How will artificial intelligence impact breast cancer research efficiency? 67
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives 65
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors 65
The interference between oxaliplatin & anti-EGFR therapies: A different hypothesis to explain the 'unexplainable' 64
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC 60
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study 58
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study 57
Definition of a tool to assess shared decision-making (SDM) on women with breast cancer: A value-based approach 56
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 56
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 56
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohort 55
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer 54
New life for retrospective study in the precision oncology era 54
From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting– a number needed to treat perspective 53
Targeted therapy in advanced gastric carcinoma: The future is beginning 53
New challenges in multimodal workout of locally advanced breast cancer 53
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 52
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature 49
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 48
Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence 48
To treat or no to treat: HER2 equivocal is the matter! 43
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 42
Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response? 40
Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions 40
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response 36
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line 35
Racial and ethnic disparities in breast cancer survival: critical appraisal of the data emerging from the randomized TAILORx 35
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors 33
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial 32
Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report 29
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 29
BRAF in metastatic colorectal cancer: the future starts now 15
Totale 9.369
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021226 0 0 0 0 0 32 47 4 42 30 49 22
2021/2022657 59 11 10 67 18 50 18 83 34 41 131 135
2022/20231.395 188 194 99 197 79 142 90 135 145 40 52 34
2023/2024748 40 164 30 34 38 151 53 43 16 19 75 85
2024/20252.005 37 28 135 59 134 51 69 57 203 312 540 380
2025/20263.239 738 265 428 901 867 40 0 0 0 0 0 0
Totale 9.369